Optimal management of a patient with recurrent nasopharyngeal carcinoma (263 views visite)
World Journal Of Clinical Cases (ISSN: 2307-8960), 2014; 2(7): 297-300.
Export to Esporta in BibTeX Export to Esporta in EndNote
Paper type Tipo di articolo: Journal Article,
Impact factor: 0.895, 5-year impact factor Impact factor a 5 anni: 1.273
Url: Not available. Non disponibile.
Keywords Parole chiave: Cetuximab, Nasopharyngeal Carcinoma, Re-Irradiation, Surgery Of Metastases, Undifferentiated,
Affiliations Affiliazioni:
*** IBB - CNR ***
Francesco Perri, Francesco Caponigro, Head and Neck Medical Oncology Unit, National Tumor Institute of Naples, 80131 Naples, Italy.
References Riferimenti:
Not available. Non disponibili.
World Journal Of Clinical Cases (ISSN: 2307-8960), 2014; 2(7): 297-300.
Export to Esporta in BibTeX Export to Esporta in EndNote
Paper type Tipo di articolo: Journal Article,
Impact factor: 0.895, 5-year impact factor Impact factor a 5 anni: 1.273
Url: Not available. Non disponibile.
Keywords Parole chiave: Cetuximab, Nasopharyngeal Carcinoma, Re-Irradiation, Surgery Of Metastases, Undifferentiated,
Affiliations Affiliazioni:
*** IBB - CNR ***
Francesco Perri, Francesco Caponigro, Head and Neck Medical Oncology Unit, National Tumor Institute of Naples, 80131 Naples, Italy.
References Riferimenti:
Not available. Non disponibili.
Optimal management of a patient with recurrent nasopharyngeal carcinoma
Nasopharyngeal carcinoma is rare in western countries, accounting for less than 1% of all malignancies. Despite prognosis is satisfactory for newly diagnosed, non-metastatic disease, management of recurrent disease is challenging, with a survival expectancy of approximately 6 mo with the use of chemotherapy as the sole salvage treatment. We report a case of recurrent nasopharyngeal carcinoma treated with a combination of chemotherapy, radiotherapy and surgery in the context of a multidisciplinary approach. A durable complete response was achieved.
Nasopharyngeal carcinoma is rare in western countries, accounting for less than 1% of all malignancies. Despite prognosis is satisfactory for newly diagnosed, non-metastatic disease, management of recurrent disease is challenging, with a survival expectancy of approximately 6 mo with the use of chemotherapy as the sole salvage treatment. We report a case of recurrent nasopharyngeal carcinoma treated with a combination of chemotherapy, radiotherapy and surgery in the context of a multidisciplinary approach. A durable complete response was achieved.
Optimal management of a patient with recurrent nasopharyngeal carcinoma
No results. Nessun risultato. |
Optimal management of a patient with recurrent nasopharyngeal carcinoma
Perri F, Della Vittoria Scarpati G, Caponigro F, Ionna F, Longo F, Buonopane S, Muto P, Di Marzo M, Pisconti S, Solla R
* Management of recurrent nasopharyngeal carcinoma: current perspectives (154 visite)
Oncotargets Ther (ISSN: 1178-6930linking), 2019 Feb 26; 12: 1583-1591.
Impact Factor: 2.272
Dettagli Esporta in BibTeX Esporta in EndNote
Bombardieri E, Ambrosini V, Aktolun C, Baum RP, Bishof-delaloye A, Del Vecchio S, Maffioli L, Mortelmans L, Oyen W, Pepe G, Chiti A
* In-111-pentetreotide scintigraphy: procedure guidelines for tumour imaging (444 visite)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2010 Jul; 37(7): 1441-1448.
Impact Factor: 5.036
Dettagli Esporta in BibTeX Esporta in EndNote
2 Records (2 escludendo Abstract e Conferenze).
Impact factor totale: 7.308 (7.308 escludendo Abstract e Conferenze).
Impact factor a 5 anni totale: 6.9 (6.9 escludendo Abstract e Conferenze).
Vai a fine pagina Versione per copia e incolla facile Esporta tutto in BibTeX Esporta tutto in EndNote
Perri F, Della Vittoria Scarpati G, Caponigro F, Ionna F, Longo F, Buonopane S, Muto P, Di Marzo M, Pisconti S, Solla R
* Management of recurrent nasopharyngeal carcinoma: current perspectives (154 visite)
Oncotargets Ther (ISSN: 1178-6930linking), 2019 Feb 26; 12: 1583-1591.
Impact Factor: 2.272
Dettagli Esporta in BibTeX Esporta in EndNote
Bombardieri E, Ambrosini V, Aktolun C, Baum RP, Bishof-delaloye A, Del Vecchio S, Maffioli L, Mortelmans L, Oyen W, Pepe G, Chiti A
* In-111-pentetreotide scintigraphy: procedure guidelines for tumour imaging (444 visite)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2010 Jul; 37(7): 1441-1448.
Impact Factor: 5.036
Dettagli Esporta in BibTeX Esporta in EndNote
2 Records (2 escludendo Abstract e Conferenze).
Impact factor totale: 7.308 (7.308 escludendo Abstract e Conferenze).
Impact factor a 5 anni totale: 6.9 (6.9 escludendo Abstract e Conferenze).
Last modified by Ultima modifica di Raffaele Berisio on in data Sunday 12 July 2020, 13:14:52
263 views visite. Last view on Ultima visita in data Friday 03 December 2021, 0:17:09
ibb.cnr.it